2372 39 11463 3 57797 document 11463 Neurocognitive_dataset_codebook.html text/html 0483edca0166fb33caa45b5d751e95f8224eff7984a5f85e2cfaf4fc94595b59 SHA256 14701 2021-07-26 15:42:27 https://datacompass.lshtm.ac.uk/id/eprint/2372/1/Neurocognitive_dataset_codebook.html 2372 1 2 text/html Text en public cc_by

Neurocognitive_dataset_codebook.html

documentation indefinite Codebook for Neurocognitive dataset 11464 6 57799 document 11464 Neurocognitive_dataset.csv text/plain 7a524c7038199149406e0c738e7327f512ecd5cbe9866b86bdb9ce031a4e7209 SHA256 29 2021-07-26 15:43:28 https://datacompass.lshtm.ac.uk/id/eprint/2372/2/Neurocognitive_dataset.csv 2372 2 1 text/plain Dataset en staffonly datasharingagreement

Neurocognitive_dataset.csv

data indefinite Neurocognitive dataset - consult description for access conditions 17378 1 95704 document 17378 indexcodes.txt text/plain 5a152b4b8343fa18bdb94b6d17c5654d2a3019d56bc369c73b3d8c6ba5304dab SHA256 2641 2025-02-07 10:27:25 https://datacompass.lshtm.ac.uk/id/eprint/2372/3/indexcodes.txt 2372 3 3 text/plain en public

indexcodes.txt

http://eprints.org/relation/isVersionOf https://datacompass.lshtm.ac.uk/id/document/11463 http://eprints.org/relation/isVolatileVersionOf https://datacompass.lshtm.ac.uk/id/document/11463 http://eprints.org/relation/isIndexCodesVersionOf https://datacompass.lshtm.ac.uk/id/document/11463 indefinite Generate index codes conversion from Text to indexcodes archive 318 disk0/00/00/23/72 2021-07-26 15:44:07 2025-10-30 09:47:47 2021-07-26 15:44:07 data_collection show Cresswell Fiona 0000-0002-5070-532X TRUE 9bdf0ebbbf78473aa6406c6077623dba Quinn Carson FALSE London School of Hygiene & Tropical Medicine, London, United Kingdom Infectious Diseases Institute, Kampala, Uganda ITCR Tuberculous meningitis HIV Neurocognitive Depression Uganda Data access is restricted in compliance with conditions outlined in the study protocol and ethics approvals. Data will only be shared with researchers and doctors for use in limited conditions (to inform dosage and route of administration of rifampicin) and requires written approval by the Institutional Review Board (IRB) or study sponsor. Data collected as part of the “High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis” (RIFT) study, a phase 2 open-label randomized trial (ISRCTN42218549). It contains information obtained from 36 patients who were diagnosed with TB meningitis and enrolled between January 14 and December 17, 2019 at Kiruddu National Referral Hospital in Kampala, Uganda. Variables include baseline clinical and laboratory results, as well as clinical statuses, functional statuses, results of depression screening, and detailed neurocognitive assessment of across motor and cognitive domains at 8 and 24 weeks of follow up. Results of neurocognitive tests are reported both as raw scores and as Z-scores standardized to a cohort of HIV-negative Ugandan age- and education-matched controls. Data access is restricted in compliance with conditions outlined in the study protocol and ethics approvals. Data will only be shared with researchers and doctors for use in limited conditions (e.g. to inform dosage and route of administration of rifampicin) and requires written approval by the Institutional Review Board (IRB) or study sponsor. 2021-07-15 completed London School of Hygiene & Tropical Medicine 10.17037/DATA.00002372 Dataset London School of Hygiene & Tropical Medicine, London, United Kingdom MeasurementsAndTests.Physical 176 UJL KM JC-JCK JJ UI restricted London, United Kingdom Wellcome Trust Medical Research Council Medical Research Council High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) Dataset Quantitative en https://doi.org/10.1186/ISRCTN42218549 other https://researchonline.lshtm.ac.uk/id/eprint/4649272 https://researchonline.lshtm.ac.uk/id/eprint/4663321 High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) Wellcome Trust http://dx.doi.org/10.13039/100010269 High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) Medical Research Council MC_UU_00027/5/ http://dx.doi.org/10.13039/501100000265 High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) Medical Research Council MC_UU_00027/5/ http://dx.doi.org/10.13039/501100000265 2021-07-15